Gastrointestinal Diseases Therapeutics Market Size to Grow by USD 1.60 Billion, And The Majority Of The Market Growth To Originate From North America - Technavio

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- The gastrointestinal diseases therapeutics market size is expected to grow by USD 1.60 billion from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 6.68% during the forecast period. According to Technavio the recent trends and developments in the pharmaceuticals industry. The report considers various factors including the impact of COVID-19 on the market, product, and revenue generated by vendors among others to estimate the size of the market. Understand the scope of our full report on the global gastrointestinal diseases therapeutics market. Download PDF sample report.

Technavio has announced its latest market research report titled Global Gastrointestinal Diseases Therapeutics Market 2022-2026
Technavio has announced its latest market research report titled Global Gastrointestinal Diseases Therapeutics Market 2022-2026

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Co Inc, Bayer AG, Biogen Inc., Boston Scientific Corp., C. H. Boehringer Sohn AG and Co. KG, Eisai Co. Ltd., Eli Lilly and Co., Evoke Pharma Inc, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Olympus Corp., OVESCO ENDOSCOPY AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA are among some of the major market participants.

The market is driven by the increasing incidence of gastrointestinal diseases. Moreover, improper diet, inactive lifestyle, stress, food sensitivity, and bacterial or viral infection are the major factors contributing to the increasing incidence of chronic and acute gastrointestinal diseases. Although factors such as the high cost of therapeutics may impede the market growth, because diseases such as Crohn's disease and ulcerative colitis are chronic IBS, which require prolonged treatment to prevent reoccurrence and chances of developing cancer. The overall cost of therapies for gastrointestinal diseases majorly includes the cost of drugs, doctor fees, and the cost of hospital visits or hospital stays. To know more about the drivers, trends and challenges Request a sample report here.

Gastrointestinal Diseases Therapeutics Market 2022-2026: Segmentation

  • Product

Anti-inflammatory and immunosuppressors are a type of drugs used for the treatment of patients with IBDs. The increasing prevalence of ulcerative colitis and Crohn's disease, the rising focus of vendors on developing biologics, and effective treatment results among the patients with IBDs are the factors contributing to the growth of the anti-inflammatory and immunosuppressors segment of the global gastrointestinal diseases therapeutics market.

  • Geography

North America is another region showing major market growth. The increasing incidence and prevalence of chronic gastrointestinal diseases, growing healthcare expenditure, and increasing preference for therapeutics over surgical procedures are driving the gastrointestinal diseases therapeutics market in North America. The gastrointestinal diseases therapeutics market report covers the following areas:

Gastrointestinal Diseases Therapeutics Market 2022-2026: Key Highlights

  • CAGR of the market during the forecast period 2022-2026.

  • Detailed information on factors that will assist gastrointestinal diseases therapeutics market growth during the next five years.

  • Estimation of the gastrointestinal diseases therapeutics market size and its contribution to the parent market.

  • Predictions on upcoming trends and changes in consumer behavior.

  • The growth of the gastrointestinal diseases therapeutics market.

  • Analysis of the market's competitive landscape and detailed information on vendors.

  • Comprehensive details of factors that will challenge the growth of the gastrointestinal diseases therapeutics market, and vendors.

Related Reports:

Gastrointestinal Diseases Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 6.68%

Market growth 2022-2026

USD 1.60 billion

Market structure

Fragmented

YoY growth (%)

7.63

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 45%

Key consumer countries

US, Germany, France, Japan, and China

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Co Inc, Bayer AG, Biogen Inc., Boston Scientific Corp., C. H. Boehringer Sohn AG and Co. KG, Eisai Co. Ltd., Eli Lilly and Co., Evoke Pharma Inc, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Olympus Corp., OVESCO ENDOSCOPY AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents:

1 Executive Summary

  • 1.1 Market overview

2 Market Landscape

  • 2.1 Market ecosystem

3 Market Sizing

  • 3.1 Market definition

  • 3.2 Market segment analysis

  • 3.3 Market size 2021

  • 3.4 Market outlook: Forecast for 2021-2026

4 Five Forces Analysis

  • 4.1 Five forces summary

  • 4.2 Bargaining power of buyers

  • 4.3 Bargaining power of suppliers

  • 4.4 Threat of new entrants

  • 4.5 Threat of substitutes

  • 4.6 Threat of rivalry

  • 4.7 Market condition

5 Market Segmentation by Drug Class

  • 5.1 Market segments

  • 5.2 Comparison by Drug Class

  • 5.3 Anti-inflammatory and immunosuppressors - Market size and forecast 2021-2026

  • 5.4 Acid neutralizers - Market size and forecast 2021-2026

  • 5.5 Other therapeutics - Market size and forecast 2021-2026

  • 5.6 Market opportunity by Drug Class

6 Customer Landscape

  • 6.1 Customer landscape overview

7 Geographic Landscape

  • 7.1 Geographic segmentation

  • 7.2 Geographic comparison

  • 7.3 North America - Market size and forecast 2021-2026

  • 7.4 Europe - Market size and forecast 2021-2026

  • 7.5 Asia - Market size and forecast 2021-2026

  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026

  • 7.7 US - Market size and forecast 2021-2026

  • 7.8 Japan - Market size and forecast 2021-2026

  • 7.9 China - Market size and forecast 2021-2026

  • 7.10 Germany - Market size and forecast 2021-2026

  • 7.11 France - Market size and forecast 2021-2026

  • 7.12 Market opportunity by geography

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers

  • 8.2 Market challenges

  • 8.3 Impact of drivers and challenges

  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview

  • 9.2 Vendor landscape

  • 9.3 Landscape disruption

  • 9.4 Industry risks

10 Vendor Analysis

  • 10.1 Vendors covered

  • 10.2 Market positioning of vendors

  • 10.3 Abbott Laboratories

  • 10.4 AbbVie Inc.

  • 10.5 AstraZeneca Plc

  • 10.6 Bausch Health Co Inc

  • 10.7 C. H. Boehringer Sohn AG and Co. KG

  • 10.8 GlaxoSmithKline Plc

  • 10.9 Johnson and Johnson

  • 10.10 Merck and Co. Inc.

  • 10.11 Takeda Pharmaceutical Co. Ltd.

  • 10.12 UCB SA

11 Appendix

  • 11.1 Scope of the report

  • 11.2 Inclusions and exclusions checklist

  • 11.3 Currency conversion rates for US$

  • 11.4 Research methodology

  • 11.5 List of abbreviations

  • disease

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Global Gastrointestinal Diseases Therapeutics Market 2022-2026
Global Gastrointestinal Diseases Therapeutics Market 2022-2026
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/gastrointestinal-diseases-therapeutics-market-size-to-grow-by-usd-1-60-billion-and-the-majority-of-the-market-growth-to-originate-from-north-america---technavio-301637637.html

SOURCE Technavio